1. Kraan H, Vrieling H, Czerkinsky C, Jiskoot W, Kersten G, Amorij JP.

Buccal and
sublingual vaccine delivery. J Control Release. 2014;190:580–92. 


2. Mestecky J, McGhee JR, Arnold RR, Michalek
 SM, Prince SJ, Babb JL. Selective
induction of an 10. immune response in human external secretions
 by ingestion of
bacterial antigen. J Clin Invest. 1978a;61(3):731–7.

3. Mestecky J, McGhee JR, Michalek SM, Arnold RR, Crago SS, Babb JL. Concept of the
local and com-
 mon mucosal immune response. Adv Exp Med Biol. 1978b;107:185–
92.

4. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11(4

Suppl):S45–53. 


5. Mestecky J, Moldoveanu Z, Elson CO. Immune response versus mucosal tolerance to

mucosally administered antigens. Vaccine. 2005;23(15):1800–3. 


6. Ley K, Laudanna C, Cybulsky MI, Nourshargh
 S. Getting to the site of inflammation:

the leuko-
 cyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678–89. 


7. Sahingur SE, Yeudall WA. Chemokine function in periodontal disease and oral cavity
cancer. Front Immunol. 2015;6:214.

8. Wu Z, Lee S, Abrams W, Weissman D, Malamud D. The N-terminal SRCR-SID domain

of gp-340 interacts with HIV type 1 gp120 sequences and inhibits viral infection. AIDS
Res Hum Retrovir. 2006;22(6):508–15.
 9. Stoddard E, Cannon G, Ni H, Kariko K,
Capodici

9. J, Malamud D, Weissman D. gp340 expressed on human genital epithelia binds HIV-1

envelope pro- tein and facilitates viral transmission. J Immunol. 2007;179(5):3126–32.

10. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells--how did we miss them?
Nat Rev Immunol. 2013;13(2):75–87.


11. Lavelle EC, Murphy C, O'Neill LAJ, Creagh EM. The role of TLRs, NLRs, and RLRs in
mucosal innate immunity and homeostasis. Mucosal Immunol. 2010;3(1):17–28.

12. Seoudi N, Bergmeier LA, Hagi-Pavli E, Bibby D, Curtis MA, Fortune F. The role of
TLR2 and 4 in Behçet's disease pathogenesis. Innate Immun. 2014;20(4):412–22.
 13. Sinon SH, Rich AM, Parachuru VP, Firth FA, Milne T, Seymour GJ. Downregulation of
toll-like receptor- mediated signalling pathways in oral lichen planus. J Oral Pathol Med.
2016;45(1):28–34.

14. Allen F, Tong AA, Huang AY. Unique transcom- partmental bridge: antigen-presenting
cells sam- pling across endothelial and mucosal barriers. Front Immunol. 2016;7:231.
15. Hussain LA, Lehner T. Comparative investigation of Langerhans' cells and potential
receptors for HIV in oral, genitourinary and rectal epithelia. Immunology.
1995;85(3):475–84.

16. Lehner T, Bergmeier L, Wang Y, Tao L, Mitchell E. A rational basis for mucosal
vaccination against HIV infection. Immunol Rev. 1999;170:183–96. 


17. Hovav A-H. Dendritic cells of the oral mucosa. Mucosal Immunol. 2014;7(1):27–37. 


18. Palm NW, Medzhitov R. Pattern recognition recep- tors and control of adaptive
immunity. Immunol Rev. 2009;227(1):221–33. 


19. Boyle JO, Gümüs ZH, Kacker A, Choksi VL, Bocker JM, Zhou XK, Yantiss RK, Hughes
DB, Du B, Judson BL, Subbaramaiah K, Dannenberg AJ. Effects of cigarette smoke on
the human oral mucosal transcrip- tome. Cancer Prev Res (Phila). 2010;3(3):266–78. 


20. Cruchley AT, Williams DM, Farthing PM, Lesch CA, Squier CA. Regional variation in
Langerhans cell dis- tribution and density in normal human oral mucosa determined using
monoclonal antibodies against CD1, HLADR, HLADQ and HLADP. J Oral Pathol Med.
1989;18(9):510–6. 


21. Cruchley AT, Williams DM, Farthing PM, Speight PM, Lesch CA, Squier CA.
Langerhans cell density in normal human oral mucosa and skin: relationship to age,
smoking and alcohol consumption. J Oral Pathol Med. 1994;23(2):55–9. 


22. Hasan MS, Ryan PL, Bergmeier LA, Fortune F. Circulating NK cells and their subsets in
Behcet's disease. Clin Exp Immunol. 2017;188(2):311–22.

23. Lanier LL. Shades of grey--the blurring view of innate and adaptive immunity. Nat Rev
Immunol. 2013;13(2):73–4. 


24. Cerutti A, Cols M, Puga I. Marginal zone B cells: vir- tues of innate-like antibody-
producing lymphocytes. Nat Rev Immunol. 2013;13(2):118–32. 


25. Brennan PJ, Brigl M, Brenner MB. Invariant natu- ral killer T cells: an innate activation
scheme linked to diverse effector functions. Nat Rev Immunol. 2013;13(2):101–17. 

26. Gold MC, Lewinsohn DM. Co-dependents: MR1- restricted MAIT cells and their
antimicrobial func- tion. Nat Rev Microbiol. 2013;11(1):14–9. 


27. Itohara S, Farr AG, Lafaille JJ, Bonneville M, Takagaki Y, Haas W, Tonegawa S.
Homing of a gamma delta thymocyte subset with homogeneous T-cell receptors to
mucosal epithelia. Nature. 1990;343(6260):754–7. 


28. McCarthy NE, Bashir Z, Vossenkamper A, Hedin CR, Giles EM, Bhattacharjee S, Brown
SG, Sanders TJ, Whelan K, MacDonald TT, Lindsay JO, Stagg AJ. Proinflammatory
Vdelta2+ T cells populate the human intestinal mucosa and enhance IFN-gamma
production by colonic alphabeta T cells. J Immunol. 2013;191(5):2752–63. 


29. McCarthy NE, Hedin CR, Sanders TJ, Amon P, Hoti I, Ayada I, Baji V, Giles EM,
Wildemann M, Bashir Z, Whelan K, Sanderson I, Lindsay JO, Stagg AJ. Azathioprine
therapy selectively ablates human Vdelta2(+) T cells in Crohn's disease. J Clin Invest.
2015;125(8):3215–25. 


30. Freysdottir J, Hussain L, Farmer I, Lau S-H, Fortune F. Diversity of gammadelta T cells
in patients with Behcet's disease is indicative of polyclonal activation. Oral Dis.
2006;12(3):271–7. 


31. Hasan A, Fortune F, Wilson A, Warr K, Shinnick T, Mizushima Y, van der Zee R,
Stanford MR, Sanderson J, Lehner T. Role of gamma delta T cells in pathogenesis and
diagnosis of Behcet's disease. Lancet. 1996;347(9004):789–94.

32. Hasan MS, Bergmeier LA, Petrushkin H, Fortune F. Gamma delta (gammadelta) T cells
and their involvement in Behcet's disease. J Immunol Res. 2015;2015:705831.

33. Bank I, Duvdevani M, Livneh A. Expansion of gam- madelta T-cells in Behcet's disease:
role of disease activity and microbial flora in oral ulcers. J Lab Clin Med.
2003;141(1):33–40.

34. Eberl M, Hintz M, Reichenberg A, Kollas AK, Wiesner J, Jomaa H. Microbial

isoprenoid biosynthe- sis and human gammadelta T cell activation. FEBS Lett.
2003;544(1-3):4–10.

35. Lehner T, Mitchell E, Bergmeier L, Singh M, Spallek R, Cranage M, Hall G, Dennis M,

Villinger F, Wang Y. The role of gammadelta T cells in generating antivi- ral factors and
beta-chemokines in protection against mucosal simian immunodeficiency virus infection.
Eur J Immunol. 2000;30(8):2245–56.
36. Kosub DA, Durudas A, Lehrman G, Milush JM, Cano CA, Jain MK, Sodora DL.
Gamma/delta T cell mRNA levels decrease at mucosal sites and increase at lymphoid
sites following an oral SIV infection of macaques. Curr HIV Res. 2008;6(6):520–30.

37. Su D, Shen M, Li X, Sun L. Roles of γδ T cells in the pathogenesis of autoimmune

diseases. Clin Dev Immunol. 2013;2013:985753.

38. Vantourout P, Hayday A. Six-of-the-best: unique con- tributions of gammadelta T cells

to immunology. Nat Rev Immunol. 2013;13(2):88–100.

39. Conti HR, Bruno VM, Childs EE, Daugherty S, Hunter JP, Mengesha BG, Saevig DL,
Hendricks MR, Coleman BM, Brane L, Solis N, Cruz JA, Verma AH, Garg AV, Hise
AG, Richardson JP, Naglik JR, Filler SG, Kolls JK, Sinha S, Gaffen SL. IL-17 receptor
sig- naling in oral epithelial cells is critical for protection against oropharyngeal
candidiasis. Cell Host Microbe. 2016;20(5):606–17.

40. Dutzan N, Konkel JE, Greenwell-Wild T, Moutsopoulos NM. Characterization of the

human immune cell network at the gingival barrier. Mucosal Immunol. 2016;9(5):1163–
72.

41. Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517(7534):293–
301.

42. Tait Wojno ED, Artis D. Innate lymphoid cells: bal- ancing immunity, inflammation,
and tissue repair in the intestine. Cell Host Microbe. 2012;12(4):445–57.

43. Hazenberg MD, Spits H. Human innate lymphoid cells. Blood. 2014;124(5):700–9.

44. McKenzie AN, Spits H, Eberl G. Innate lymphoid cells in inflammation and immunity.
Immunity. 2014;41(3):366–74.

45. Klose CS, Artis D. Innate lymphoid cells as regulators of immunity, inflammation and
tissue homeostasis. Nat Immunol. 2016;17(7):765–74.

46. Simmerman E, Qin X, Marshall B, Perry L, Cai L, Wang T, Yu J, Akbari O, Baban B.

Innate lymphoid cells: a paradigm for low SSI in cleft lip repair. J Surg Res.
2016;205(2):312–7.

47. Russell MW, Bergmeier LA, Zanders ED, Lehner 
 T. Protein antigens of Streptococcus
Mutans: puri- fication and properties of a double antigen and its protease-resistant
component. Infect Immun. 1980a;28(2):486–93. 

48. Russell MW, Zanders ED, Bergmeier LA, Lehner T. Affinity purification and
characterization of protease-susceptible antigen I of Streptococcus Mutans. Infect Immun.
1980b;29(3):999–1006. 


49. Challacombe SJ, Bergmeier LA, Czerkinsky C, Rees AS. Natural antibodies in man to
Streptococcus Mutans: specificity and quantification. Immunology. 1984;52(1):143–50.



50. ChallacombeSJ,RussellMW,HawkesJ.Passage of intact IgG from plasma to the oral

cavity via crevicular fluid. Clin Exp Immunol. 1978a; 34(3):417–22.

51. Challacombe SJ, Russell MW, Hawkes JE, Bergmeier LA, Lehner T. Passage of
immunoglobulins from plasma to the oral cavity in rhesus monkeys. Immunology.
1978b;35(6):923–31. 


52. Lehner T, Ma JK, Kelly CG. A mechanism of pas- sive immunization with monoclonal
antibodies to a 185,000 M(r) streptococcal antigen. Adv Exp Med Biol. 1992;327:151–
63. 


53. Ma JK, Hunjan M, Smith R, Kelly C, Lehner T. An investigation into the mechanism of
protection by local passive immunization with monoclonal anti- bodies against
Streptococcus Mutans. Infect Immun. 1990;58(10):3407–14. 


54. Ma JK, Lehner T. Prevention of colonization of Streptococcus Mutans by topical

application of monoclonal antibodies in human subjects. Arch Oral Biol.
1990;35(Suppl):115S–22S. 


55. Booth V, Ashley FP, Lehner T. Passive immunization with monoclonal antibodies
against Porphyromonas gingivalis in patients with periodontitis. Infect Immun.
1996;64(2):422–7. 


56. Booth V, Lehner T. Characterization of the Porphyromonas gingivalis antigen recognized

by a monoclonal antibody which prevents colonization by the organism. J Periodontal
Res. 1997;32(1 Pt 1):54–60. 


57. Kelly CG, Booth V, Kendal H, Slaney JM, Curtis MA, Lehner T. The relationship
between colonization and haemagglutination inhibiting and B cell epitopes of
Porphyromonas gingivalis. Clin Exp Immunol. 1997;110(2):285–91. 


58. Curtis MA, Zenobia C, Darveau RP. The relationship of the oral microbiotia to
periodontal health and dis- ease. Cell Host Microbe. 2011;10(4):302–6. 

59. Hajishengallis G. Periodontitis: from microbial immune subversion to systemic
inflammation. Nat Rev Immunol. 2015;15(1):30–44. 


60. Brandtzaeg P. Secretory immunity with special refer- ence to the oral cavity. J Oral
Microbiol. 2013;5. 


61. Woof JM, Mestecky J. Mucosal immunoglobulins. 
 Immunol Rev. 2005;206:64–82. 


62. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of
murine helper T cell clone. I. Definition according to profiles of lym- phokine activities
and secreted proteins. J Immunol. 1986;136(7):2348–57.

63. Amatya N, Garg AV, Gaffen SL. IL-17 signal- ing: the yin and the Yang. Trends
Immunol. 2017;38(5):310–22.

64. Wadia P, Atre N, Pradhan T, Mistry R, Chiplunkar S. Heat shock protein induced TCR
gammadelta gene rearrangements in patients with oral cancer. Oral Oncol.
2005;41(2):175–82.
65. Wu R-Q, Zhang D-F, Tu E, Chen Q-M, Chen W. The mucosal immune system in the
oral cavity-an orchestra of T cell diversity. Int J Oral Sci. 2014a;6(3):125–32.

66. .Jotwani R, Pulendran B, Agrawal S, Cutler CW. Human dendritic cells respond to
Porphyromonas gingivalis LPS by promoting a Th2 effector response in vitro. Eur J
Immunol. 2003;33(11):2980–6.

67. Pulendran B, Kumar P, Cutler CW, Mohamadzadeh M, Van Dyke T, Banchereau J.

Lipopolysaccharides from distinct pathogens induce different classes of immune
responses in vivo. J Immunol. 2001;167(9):5067–76.

68. Pulendran B, Lingappa J, Kennedy MK, Smith J, Teepe M, Rudensky A, Maliszewski

CR, Maraskovsky E. Developmental pathways of dendritic cells in vivo: distinct
function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated
mice. J Immunol. 1997;159(5):2222–31.

69. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, Maliszewski CR.
Distinct den- dritic cell subsets differentially regulate the class of immune response in
vivo. Proc Natl Acad Sci U S A. 1999;96(3):1036–41.

70. Cutler CW, Jotwani R. Dendritic cells at the oral mucosal interface. J Dent Res.
2006;85(8):678–89.

71. Bhingare AC, Ohno T, Tomura M, Zhang C, Aramaki O, Otsuki M, Tagami J, Azuma
M. Dental pulp den- dritic cells migrate to regional lymph nodes. J Dent Res.
2014;93(3):288–93.
72. Allam JP, Peng WM, Appel T, Wenghoefer M, Niederhagen B, Bieber T, Bergé S,
Novak N. Toll- like receptor 4 ligation enforces tolerogenic proper- ties of oral mucosal
Langerhans cells. J Allergy Clin Immunol. 2008a;121(2):368–374.e361.

73. Allam JP, Stojanovski G, Friedrichs N, Peng W, Bieber T, Wenzel J, Novak N.

Distribution of Langerhans cells and mast cells within the human oral mucosa: new
application sites of allergens in sublingual immu- notherapy? Allergy. 2008b;63(6):720–
7.

74. Novak N, Bieber T, Allam J-P. Immunological mecha- nisms of sublingual allergen-
specific immunotherapy. Allergy. 2011;66(6):733–9.

75. Novak N, Gros E, Bieber T, Allam J-P. Human skin and oral mucosal dendritic cells as
'good guys' and 'bad guys' in allergic immune responses. Clin Exp Immunol.
2010;161(1):28–33.

76. Novak N, Haberstok J, Bieber T, Allam JP. The immune privilege of the oral mucosa.
Trends Mol Med. 2008;14(5):191–8.

77. Hamedi M, Bergmeier LA, Hagi-Pavli E, Vartoukian SR, Fortune F. Differential

expression of suppressor of cytokine signalling proteins in Behçet's disease. Scand J
Immunol. 2014;80(5):369–76. 


78. Vartoukian SR, Tilakaratne WM, Seoudi N, Bombardieri M, Bergmeier L, Tappuni AR,
Fortune F. Dysregulation of the suppressor of cytokine signal- ling 3-signal transducer
and activator of transcrip- tion-3 pathway in the aetiopathogenesis of Sjogren's syndrome.
Clin Exp Immunol. 2014;177(3):618–29. 


79. Conti HR, Peterson AC, Brane L, Huppler AR, Hernández-Santos N, Whibley N, Garg
AV, Simpson- Abelson MR, Gibson GA, Mamo AJ, Osborne LC, Bishu S, Ghilardi N,
Siebenlist U, Watkins SC, Artis D, McGeachy MJ, Gaffen SL. Oral-resident natural Th17
cells and γδ T cells control oppor- tunistic Candida Albicans infections. J Exp Med.
2014;211(10):2075–84. 


80. Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, Ho AW, Hai JH, Yu JJ,
Jung JW, Filler SG, Masso-Welch P, Edgerton M, Gaffen SL. Th17 cells and IL-17
receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp
Med. 2009;206(2):299–311. 


81. Bai J, Lin M, Zeng X, Zhang Y, Wang Z, Shen J, Jiang L, Gao F, Chen Q. Association of
polymorphisms in the human IFN-gamma and IL-4 gene with oral lichen planus: a study
in an ethnic Chinese cohort. J Interf Cytokine Res. 2008;28(6):351–8. 


82. Romani L. Immunity to fungal infections. Nat Rev Immunol. 2011;11(4):275–88. 


83. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic- Plese S. Simvastatin inhibits IL-17
secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the
expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol.
2008a;180(10):6988–96. 


84. Zhang Y, Lin M, Zhang S, Wang Z, Jiang L, Shen J, Bai J, Gao F, Zhou M, Chen Q. NF-
kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: a
study in an ethnic Chinese popula- tion. Cytokine. 2008b;41(2):144–9. 


85. Cochran DL. Inflammation and bone loss in periodon- tal disease. J Periodontol.
2008;79(8 Suppl):1569–76. 


86. Gemmell E, Yamazaki K, Seymour GJ. Destructive periodontitis lesions are determined
by the nature of the lymphocytic response. Crit Rev Oral Biol Med. 2002;13(1):17–34.


87. Wu RQ, Zhang DF, Tu E, Chen QM, Chen W. The mucosal immune system in the oral
cavity-an orchestra of T cell diversity. Int J Oral Sci. 2014b;6(3):125–32.

88. Sun JB, Czerkinsky C, Holmgren J. Mucosally induced immunological tolerance,

regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand J Immunol.
2010;71(1):1–11.


89. Stanford M, Whittall T, Bergmeier LA, Lindblad M, Lundin S, Shinnick T, Mizushima

Y, Holmgren J, Lehner T. Oral tolerization with peptide 336- 351 linked to cholera toxin
B subunit in prevent- ing relapses of uveitis in Behcet's disease. Clin Exp Immunol.
2004;137(1):201–8.

90. Novak N, Allam J-P. Mucosal dendritic cells in allergy and immunotherapy. Allergy.
2011;66(Suppl 95):22–4.

91. Mascarell L, Saint-Lu N, Moussu H, Zimmer A, Louise A, Lone Y, Ladant D, Leclerc C,

Tourdot S, Van Overtvelt L, Moingeon P. Oral macrophage-like cells play a key role in
tolerance induction follow- ing sublingual immunotherapy of asthmatic mice. Mucosal
Immunol. 2011a;4(6):638–47.

92. Mascarell L, Zimmer A, Van Overtvelt L, Tourdot S, Moingeon P. Induction of allergen-

specific tolerance via mucosal routes. Curr Top Microbiol Immunol. 2011b;352:85–105.

93. Moingeon P, Mascarell L. Induction of tolerance via the sublingual route: mechanisms
and applications. Clin Dev Immunol. 2012;2012:623474.
94. Yoshitomi T, Nakagami Y, Hirahara K, Taniguchi Y, Sakaguchi M, Yamashita M.
Intraoral administra- tion of a T-cell epitope peptide induces immunologi- cal tolerance in
cry j 2-sensitized mice. J Pept Sci. 2007;13(8):499–503.

95. Coelho ED, Arrais JP, Matos S, Pereira C, Rosa N, Correia MJ, Barros M, Oliveira JL.
Computational prediction of the human-microbial oral interactome. BMC Syst Biol.
2014;8(1):24.

96. Douglas CWI. Bacterial-protein interactions in the oral cavity. Adv Dent Res.
1994;8(2):254–62.

97. Salvucci E. Microbiome, holobiont and the net of life. Crit Rev Microbiol.
2016;42(3):485–94.